If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

There are two main types of RVO: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). In CRVO, the buildup occurs in the eye’s central retinal vein and in BRVO ...

The prevalence of central RVO ranges from 0.1% to 0.2% of the global population, while branch RVO affects anywhere from 0.5% to 2% of the population. 3 “With these pivotal results in retinal vein ...

for aflibercept injection 8mg for the treatment of macular edema following retinal vein occlusion (RVO) and monthly dosing across all approved indications. The sBLA was supported by data from the ...

The FDA has accepted Regeneron Pharmaceuticals’ sBLA for Eylea HD (aflibercept) injection 8mg for priority review.

High cholesterol is a common health condition that doesn't usually produce any noticeable symptoms, but there are some ...

One ocular sign of high cholesterol is a bluish ... that high cholesterol was twice as common in people with central retinal vein occlusion compared to people who did not have the eye condition ...

In their study, 16 ophthalmologists, including attending physicians and residents with levels of experience ranging from 1 to ...